Partner4Biotech, Genopole’s new meeting format to allow you to connect to large corporate groups.
Are you part of a research laboratory, a company or a project in the biotech sector ?
Are you looking for funds or collaborations to boost your development ?
Sign up for our Partner4Biotech Day with Merck on June 18th !
In the morning, we will hold a seminar with international speakers to present the latest advances of Merck. The topics will range from Gene Editing to Scale up issues. Finally, Business Developers and Investors will explain how to approach a large group.
In the afternoon, we will put these elements into practice and move on to one-on-one meetings with Merck experts :
→ Business developers from Merck
→ Merck Ventures, which invests from early-stage projects to public companies in all fields (healthtech, medtech, ag-tech, foodtech etc….).
These appointments are reserved, exclusively on request, to the Genopole members.
Detailed program :
||Door opening & breakfast |
||Welcome and opening, by Jean-Marc Grognet, General Manager of Genopole|
||Who is Merck ? by Catherine Salgues, Key Account Manager and Sylviane Baghdassarian, Marketing Manager WE Research Solutions|
|10:00|| Gene Editing & Cell Model Engineering |
→ Gillian Browne, Global Market Development Scientist, will showcase Merck’s latest CRISPR Cas9 technologies and services to design cell models for drug discovery and disease modeling.
Merck has been at the forefront of gene editing solutions for well over a decade. Our commitment to providing cutting edge research technologies continues through the CRISPR revolution that has emerged in recent years. This seminar will examine some of the newest CRISPR/Cas9 technologies from Merck, share some strategies for successful generation of modified cell lines as well as highlight the services Merck provides for customized cell models in drug discovery and disease modeling.
|10:45||Process Solution : Normal Flow Filtration, design and scale-up challenges|
→ Marine Maszelin, Biomanufacturing Engineer, will discuss design and scale up challenges when designing a normal flow filtration step (aseptic, virus clearance, clarification) with the goal to ensure a rapid rise by reducing risks.
|11:45||How to pitch to big pharmas and corporate ventures ? |
→ Arnaud Autret, Investment Principal, Therese Liechtenstein, Associate in the Healthcare Fund and Ricardo Castro, Associate in the Life Science Fund. This session will provide insights & perspectives from Merck Ventures & Merck Business development.
||Networking Lunch (possibility to discuss with the speakers)|
→ Merck scientific experts will be available for meeting on booths
→ B2B Meeting sessions with Business Developers & Ventures (open to Genopole members only – meetings will be confirmed ahead of this event) - deadline May 31st
Event is free of charge but registration is required. Please fill out the registration form below :